Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2

New England Journal of Medicine

Volumn 344, Issue 11, 2001, Pages 783-792

  Slamon, Dennis J ^a   Leyland Jones, Brian ^b   Shak, Steven ^c   Fuchs, Hank ^d   Paton, Virginia ^c   Bajamonde, Alex ^c   Fleming, Thomas ^e   Eiermann, Wolfgang ^f   Wolter, Janet ^g   Pegram, Mark ^a   Baselga, Jose ^h   Norton, Larry ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c GENENTECH INC   (United States)

^d IntraBiotics Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Frauenklinik Vom Roten Kreuz ^*  (Germany)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; EPIRUBICIN; FEMALE; HEART DISEASES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 0035869407     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103153441101     Document Type: Article

References (33)

1. Cancer statistics 1999
2. Treatment of breast cancer
3. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
4. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
5. Tyrosine Kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
6. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
7. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
8. Human breast cancer: Correlation of relapse and survival with amplification of the HER2-2/neu oncogene
9. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
10. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
11. HER-2/neu expression in node- negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
12. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review
13. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells
14. erbB-2 Is a potent oncogene when overexpressed in NIH/3T3 cells
15. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
16. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor
17. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
18. p185HER2 Monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
19. Monodonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
20. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
21. Humanization of an anti- p185HER2 antibody for human cancer therapy
22. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
23. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
24. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression
25. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
26. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
27. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
28. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
29. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
30. New treatments for breast cancer
31. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
32. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial
33. Risk factors for doxorubicin- induced congestive heart failure